Medley Therapeutics (formerly YAP Therapeutics) has dosed the first cohort (n=3) with YAP101 in the Phase 1 SALVADOR-HF trial at The Texas Heart Institute at Baylor College of Medicine in the Baylor ...
MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News: Celyad Oncology (Euronext: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (the “Company”), today announces the publication of the ...
STUART, Fla.--(BUSINESS WIRE)-- Scientists from Cognigenics have made significant progress in developing precision-based therapeutics for neurological disorders. In a groundbreaking study, they ...
Neuropharmacology Laboratory of Physiology Department, Basic Medical School of Nanchang University, Nanchang 330006, PR China Jiangxi Provincial Key Laboratory of Autonomic Nervous Function and ...
Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. Uncovering the functions of genes in a complex ...
Chimeric antigen receptor (CAR) T cells targeting CD19 antigen have produced remarkable clinical outcomes for cancer patients. However, identifying measures to enhance effector function remains one of ...
Salmonella Typhi is a human-restricted bacterial pathogen that causes typhoid fever, a life-threatening systemic infection. A fundamental aspect of S. Typhi pathogenesis is its ability to survive in ...
A new chimeric antigen receptor (CAR) T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA) has been approved for a phase 1 clinical trial in relapsed/refractory multiple myeloma. The ...
“This is just a different way of achieving TCR knockdown and probably enabled them to generate intellectual property,” said Dr Atanackovic. “I cannot think of any major clinically relevant advantages ...
In an interview with Targeted Oncology, David E. Gilham, PhD, discussed the findings from the single vector multiplexed short-hairpin RNA approach to concurrently knockdown the expression of multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback